Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 11Thoracic 3Other solid neoplasm 2Head & Neck 2Genitourinary 2Sarcoma 1Gynecologic 1

Conditions

Prostatic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Magnetic Resonance Spectroscopy 87Specimen Handling 76pembrolizumab 74enzalutamide 57Radiosurgery 57Radiotherapy 51Docetaxel 50Androgen Antagonists 48Gemcitabine 43Nivolumab 40darolutamide 39Prednisone 35Abiraterone Acetate 33enfortumab vedotin 32Biopsy 31Cisplatin 30Carboplatin 29apalutamide 28Standard of Care 28cabozantinib 27Pluvicto 27abiraterone 26Blood Specimen Collection 25Radiation 23Leuprolide 23Ipilimumab 23X-Rays 18relugolix 17Triptorelin Pamoate 17Surveys and Questionnaires 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × envafolimab × Genitourinary × Clear all
NCT05024214 2026-03-25

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

3D Medicines

Phase 1/2 Recruiting
170 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

NCT06663007 2024-10-29

RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure

Tianjin Medical University Second Hospital

Phase 1/2 Recruiting
72 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡